Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI response is supported by the supplied VIIBRYD label excerpts: the suicidality monitoring/counseling for adolescents/young adults (5.1 and 17), pediatric suicidality risk and lack of established pediatric efficacy/safety (8.4), and postmarketing psychiatric adverse reactions including suicide attempt/suicidal ideation (6.2). The response does not introduce contradictions.
Category Scores
Accurate Statements
Vilazodone is indicated for the treatment of major depressive disorder (MDD) in adults.
Not verifiable from the provided label excerpts (only suicidality-related sections 5.1, 8.4, 6.2, 17 are included). Marked as partially supported due to absence of indication text in supplied material.
There are no additional FDA-labeled indications described here for anxiety disorders, obsessive-compulsive disorder (OCD), or other psychiatric conditions.
Supported only in the context of the provided excerpts (no such indications appear in the supplied label text). Not verifiable globally because the full Indications section is not included.
FDA label supports warning/monitoring regarding suicidal thoughts/behaviors in adolescents/young adults and pediatric patients; suicidality is listed in postmarketing adverse reactions.
5.1 (increased risk in patients age 24 years and younger; monitor all antidepressant-treated patients; counsel caregivers; consider changing/discontinuing if emergent suicidality), 8.4 (pediatric suicidality risk; safety/effectiveness not established in pediatric MDD; efficacy not demonstrated), 6.2 (postmarketing adverse reactions include suicide attempt and suicidal ideation), 17 (patient/caregiver counseling to watch for suicidality and report symptoms).
Unsupported Statements
Vilazodone is indicated for the treatment of major depressive disorder (MDD) in adults.
The supplied label excerpts do not include the Indications section text; therefore adult MDD indication cannot be confirmed from the provided material.
There are no additional FDA-labeled indications described here for anxiety disorders, obsessive-compulsive disorder (OCD), or other psychiatric conditions.
The conclusion is limited to what is present in the supplied excerpts; the full FDA label Indications section is not provided, so absence of other indications cannot be confirmed.
Contradictions
Important Omissions
No contraindications, other boxed warnings/precautions, drug interactions, dosing/administration details, or other monitoring elements were addressed (not required for the user’s stated suicidality-focused claim).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response reflects on-label suicidality risk warnings and monitoring/counseling from the supplied sections and does not add unlabelled safety claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Adult MDD indication statements are not verifiable from the provided label excerpts.
Suggested Improvement
Limit indication-related claims to what is included in the provided excerpts, or include the label Indications section to substantiate the adult MDD indication.